Operating Lease, Payments of Y-mAbs Therapeutics, Inc. from 31 Mar 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Y-mAbs Therapeutics, Inc. quarterly and annual Operating Lease, Payments in USD history and change rate from 31 Mar 2019 to 31 Mar 2025.
  • Y-mAbs Therapeutics, Inc. Operating Lease, Payments for the quarter ending 31 Mar 2025 was $244,000, a 2.8% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. Operating Lease, Payments for the twelve months ending 31 Mar 2025 was $982,000, a 6.4% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Operating Lease, Payments for 2024 was $989,000, a 6.4% decline from 2023.
  • Y-mAbs Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $1,057,000, a 54% decline from 2022.
  • Y-mAbs Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $2,286,000, a 3.2% increase from 2021.
Source SEC data
View on sec.gov
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Change (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $982,000 $244,000 -$7,000 -2.8% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $989,000 $246,000 -$20,000 -7.5% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $1,009,000 $247,000 -$19,000 -7.1% 01 Jul 2024 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $1,028,000 $245,000 -$21,000 -7.9% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $1,049,000 $251,000 -$8,000 -3.1% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,057,000 $266,000 -$331,000 -55% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $1,388,000 $266,000 -$215,000 -45% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $1,603,000 $266,000 -$335,000 -56% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $1,938,000 $259,000 -$348,000 -57% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $2,286,000 $597,000 +$22,000 +3.8% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $2,264,000 $481,000 -$67,000 -12% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,331,000 $601,000 +$52,000 +9.5% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,279,000 $607,000 +$63,000 +12% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $2,216,000 $575,000 -$79,000 -12% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $2,295,000 $548,000 +$347,000 +173% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $1,948,000 $549,000 +$344,000 +168% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2021 Q3
Q1 2021 $1,604,000 $544,000 +$356,000 +189% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $1,248,000 $654,000 +$468,000 +252% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $780,000 $201,000 +$13,000 +6.9% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $767,000 $205,000 +$5,000 +2.5% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $762,000 $188,000 +$156,000 +488% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $606,000 $186,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $188,000 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $200,000 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $32,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1

Y-mAbs Therapeutics, Inc. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $989,000 -$68,000 -6.4% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $1,057,000 -$1,229,000 -54% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $2,286,000 +$70,000 +3.2% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $2,216,000 +$968,000 +78% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $1,248,000 +$642,000 +106% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $606,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.